D. Boral Capital Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)

Anixa Biosciences (NASDAQ:ANIX)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a report issued on Wednesday,Benzinga reports. They presently have a $10.00 price target on the stock. D. Boral Capital’s price objective would indicate a potential upside of 271.75% from the stock’s previous close.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Anixa Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Anixa Biosciences in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.50.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $2.69 on Wednesday. The firm has a market cap of $90.19 million, a price-to-earnings ratio of -8.15 and a beta of 0.57. Anixa Biosciences has a 52 week low of $2.33 and a 52 week high of $5.46. The firm has a 50-day moving average price of $2.84 and a two-hundred day moving average price of $3.50.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. As a group, sell-side analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current year.

Insiders Place Their Bets

In other Anixa Biosciences news, Director Arnold M. Baskies acquired 10,000 shares of Anixa Biosciences stock in a transaction that occurred on Wednesday, January 28th. The stock was acquired at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the purchase, the director owned 135,000 shares of the company’s stock, valued at approximately $410,400. This represents a 8.00% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 26.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new position in Anixa Biosciences in the 4th quarter valued at approximately $161,000. Millennium Management LLC purchased a new position in Anixa Biosciences in the 4th quarter valued at approximately $38,000. 683 Capital Management LLC purchased a new position in Anixa Biosciences in the 4th quarter valued at approximately $355,000. Cetera Investment Advisers purchased a new position in Anixa Biosciences in the 4th quarter valued at approximately $35,000. Finally, ExodusPoint Capital Management LP purchased a new position in Anixa Biosciences in the 4th quarter valued at approximately $293,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.